Alphamab Oncology (9966.HK)
Company Info
Highlights
HK$7.55B
43.61
HK$2.00 - HK$8.73
HK$4.75
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of HK$10,000 in Alphamab Oncology, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Alphamab Oncology (9966.HK) returned 104.86% year-to-date (YTD) and 43.98% over the past 12 months.
9966.HK
104.86%
18.71%
85.27%
43.98%
-15.91%
N/A
^GSPC (Benchmark)
-3.70%
13.67%
-5.18%
9.18%
14.14%
10.43%
Monthly Returns
The table below presents the monthly returns of 9966.HK, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -7.43% | 81.48% | 41.16% | -22.17% | 10.99% | 104.86% | |||||||
| 2024 | -40.51% | 27.09% | -9.76% | 4.86% | -46.53% | -5.51% | -7.50% | 11.26% | 91.09% | -20.55% | 1.60% | -8.14% | -47.29% |
| 2023 | 21.11% | 11.01% | -9.23% | 16.08% | -47.71% | -6.50% | 20.19% | -4.00% | -0.35% | 33.72% | -45.13% | 5.23% | -38.52% |
| 2022 | -26.62% | -7.52% | -13.87% | 1.76% | -4.20% | 4.39% | -19.04% | 21.83% | -23.56% | -9.67% | 60.62% | 22.03% | -20.59% |
| 2021 | -18.30% | -1.95% | -13.65% | 26.47% | 41.50% | 23.33% | -13.48% | -6.98% | -11.80% | -8.84% | 18.16% | -28.42% | -16.46% |
| 2020 | -1.29% | 27.21% | -11.83% | 9.68% | 8.59% | -2.38% | -6.77% | -1.55% | -8.34% | 3.17% | -2.94% | 7.25% | 16.29% |
| 2019 | 3.70% | 3.70% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
With an overall rank of 76, 9966.HK is among the top 24% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Alphamab Oncology (9966.HK) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Alphamab Oncology. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Alphamab Oncology was 92.36%, occurring on Jul 30, 2024. The portfolio has not yet recovered.
The current Alphamab Oncology drawdown is 74.16%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -92.36% | Jul 15, 2021 | 749 | Jul 30, 2024 | — | — | — |
| -56.75% | May 21, 2020 | 226 | Apr 20, 2021 | 23 | May 24, 2021 | 249 |
| -30.77% | Feb 27, 2020 | 16 | Mar 19, 2020 | 37 | May 15, 2020 | 53 |
| -22.29% | May 25, 2021 | 9 | Jun 4, 2021 | 13 | Jun 24, 2021 | 22 |
| -13.51% | Dec 17, 2019 | 17 | Jan 13, 2020 | 18 | Feb 10, 2020 | 35 |
Volatility
Volatility Chart
The current Alphamab Oncology volatility is 40.35%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Alphamab Oncology over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Alphamab Oncology is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for 9966.HK, comparing it with other companies in the Biotechnology industry. Currently, 9966.HK has a P/E ratio of 43.6. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for 9966.HK relative to other companies in the Biotechnology industry. Currently, 9966.HK has a P/S ratio of 11.9. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for 9966.HK in comparison with other companies in the Biotechnology industry. Currently, 9966.HK has a P/B value of 3.9. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |